



16 October 2026

Chair Transition

SomnoMed Limited (ASX “SOM” or the Company), the leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), announces that Mr Guy Russo will retire from the Board at the Company’s Annual General Meeting on 23 November 2026 and will not stand for re-election. The Board has selected current Non-Executive Director, Mr Andrew Price to succeed him as Chair.

Mr Russo has served as Chair of SomnoMed since August 2020, stewarding the Company through revenue and profitability growth and operational and financial turnaround, despite challenging market conditions. The Board thanks Mr Russo for his leadership and commitment.

Mr Russo said, “It has been a privilege to serve as Chair of SomnoMed over the past six years. I am grateful to my fellow directors, our management team and our people around the world for their commitment through both the progress and the challenges of that period.

“Andrew brings a strong background in the medical device industry and has experienced the challenges and opportunities as operations scale. I have great confidence in Andrew and look forward to a seamless handover.”

Mr Price joined the SomnoMed Board in January 2025 following a 25-year career at Resmed. His senior executive roles spanned global product development, project management and business development. As Chief Supply Chain Officer, he led Resmed’s end-to-end supply chain, including supplier management, manufacturing, logistics, distribution, quality assurance and regulatory affairs.

“I am honoured to have been selected as SomnoMed’s next Chair and thank Guy for his leadership and commitment to the Company. In my time as non-Executive Director, I have appreciated the opportunity to learn from Guy and my fellow directors,” Mr Price commented.

“SomnoMed has an important opportunity to expand access to effective oral appliance treatment. Our task is to build on the operational progress already made and translate our product innovation, clinical relationships and global capabilities into sustainable growth and long-term shareholder value. I look forward to working with our Chief Executive Officer, Karen Borg, the leadership team and the Board to help realise the opportunity,” added Mr Price.

Mr Price holds an Industrial Design degree from the University of Technology Sydney, has completed INSEAD’s Advanced Management Program in Singapore and is a Graduate of the Australian Institute of Company Directors.

SomnoMed has commenced a search for an additional non-executive director to be appointed to the Board, targeting appropriate industry expertise.

---ends---

This release has been approved by the Board of SomnoMed Limited.

For further information please contact

Investor Relations: ir@somnomed.com

SomnoMed Limited - 20 Clarke St, Crows Nest, NSW, Australia 2065

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>